Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
Use
This test assesses the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease by using a GALAD score. The GALAD model score combines information on gender, age, alpha-fetoprotein (AFP), AFP-L3, and des-gamma-carboxy prothrombin (DCP) with demonstrated higher diagnostic accuracy for HCC compared to these markers used alone or in combination, and its performance has been reported to be superior to ultrasound for HCC detection.
Special Instructions
Not provided.
Limitations
Serum markers used in this test may vary by method and are not fully specific for malignancy. Elevated marker levels can occur in conditions other than HCC, such as chronic liver disease or during pregnancy, which could lead to false positives. Results should be interpreted alongside clinical evaluation and imaging. Caution is advised, as method interference from heterophile antibodies may arise. This test is inappropriate for assessing patients who are pregnant.
FDA ApprovedNew York Approved
Methodology
Other
Biomarkers
AFP-L3
AnalyteAlpha-fetoprotein (AFP)
AnalyteDes-Gamma-Carboxy Prothrombin (DCP)
Analyte
LOINC Codes
- 96452-8 - Hep Ca Risk Pnl SerPl
- 1834-1 - AFP SerPl-mCnc
- 42332-7 - AFP L3 MFr SerPl
- 69048-7 - Immunologist review
- 34444-0 - Acarboxyprothrombin SerPl-mCnc
- 96450-2 - GALAD Score
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Storage Instructions
Frozen preferred: 90 days. Refrigerated: 5 days.
Causes for Rejection
Gross hemolysis is cause for rejection. Gross lipemia and icterus are acceptable.
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |
| Frozen | 90 days |